JV moves Immucor closer to direct presence in Japan:
This article was originally published in Clinica
Immucor is to take a majority interest in a new joint venture with the Japanese distributor of its blood transfusion diagnostics, Kainos Laboratories. It will pay $3.7m for a 51% initial stake in the venture, which will assume responsibility for Immucor's distribution in Japan. Eventually, the Norcross, Georgia-based company expects to buy the business outright and assume direct distribution of its products in Japan, the third-largest transfusion diagnostics market after the US and Europe.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.